This company is no longer active
PCBK Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sesen Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.25 |
| 52 Week High | US$18.19 |
| 52 Week Low | US$6.88 |
| Beta | 0.83 |
| 1 Month Change | -4.21% |
| 3 Month Change | 3.08% |
| 1 Year Change | -8.66% |
| 3 Year Change | -22.36% |
| 5 Year Change | -41.71% |
| Change since IPO | -31.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCBK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -4.9% | -1.5% |
| 1Y | -8.7% | -19.9% | 0.9% |
Return vs Industry: PCBK underperformed the German Biotechs industry which returned 10.9% over the past year.
Return vs Market: PCBK underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| PCBK volatility | |
|---|---|
| PCBK Average Weekly Movement | 18.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PCBK's share price has been volatile over the past 3 months.
Volatility Over Time: PCBK's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | sesenbio.com |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
| PCBK fundamental statistics | |
|---|---|
| Market cap | €2.42b |
| Earnings (TTM) | -€18.84m |
| Revenue (TTM) | €37.90m |
64.0x
P/S Ratio-128.7x
P/E RatioIs PCBK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCBK income statement (TTM) | |
|---|---|
| Revenue | US$40.00m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$38.02m |
| Other Expenses | US$57.90m |
| Earnings | -US$19.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 95.04% |
| Net Profit Margin | -49.71% |
| Debt/Equity Ratio | 0% |
How did PCBK perform over the long term?
See historical performance and comparison